Europe Sarcopenia Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Europe sarcopenia treatment market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing at a CAGR of 4.6% during the forecast period of 2023 to 2030.

Market Segmentation

Europe Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Sarcopenia Treatment Market Dynamics

Drivers
Rising prevalence of sarcopenia
Restraint
Lack of standardized diagnosis
Opportunity
Strategic initiatives by market players

Market Players

Some of the major market players operating in the Europe sarcopenia treatment market are:

Abbott.
Nestle Health Science (A subsidary of Nestle S.A.)
Novartis AG
Sanofi
Haleon Group of Companies.
BASF SE
DSM
Fermenta Biotech Limited
AstaReal Co., Ltd.
Metagenics
Wellona Pharma
The Vitamin Company India
Healing Pharma India Pvt. Ltd.
OPKO Health, Inc.
NMD PHARMA A/S
Regeneron Pharmaceuticals Inc.
Biophytis
ARMGO Pharma, Inc.
Rejuvenate Biomed NV.

1 INTRODUCTION 26

1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE EUROPE SARCOPENIA TREATMENT MARKET 26
1.4 CURRENCY AND PRICING 28
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28

2 MARKET SEGMENTATION 31

2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 38
2.8 MARKET END USER COVERAGE GRID 39
2.9 DBMR MARKET POSITION GRID 40
2.10 VENDOR SHARE ANALYSIS 42
2.11 SECONDARY SOURCES 43
2.12 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 47

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES MODEL 49
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 50

5 EUROPE SARCOPENIA TREATMENT MARKET: REGULATIONS 51

5.1 REGULATIONS IN U.S. 51
5.2 REGULATIONS IN EUROPE 51
5.3 REGULATIONS IN AUSTRALIA 52
5.4 REGULATIONS IN SOUTH AFRICA 52

6 MARKET OVERVIEW 53

6.1 DRIVERS 55
- 6.1.1 RISING PREVALENCE OF SARCOPENIA 55
- 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 55
- 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 56
6.2 RESTRAINTS 57
- 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 57
- 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 57
6.3 OPPORTUNITIES 58
- 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 58
- 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 58
6.4 CHALLENGES 59
- 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 59
- 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 60

7 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 61

7.1 OVERVIEW 62
7.2 VITAMIN/DIETARY SUPPLEMENTS 65
- 7.2.1 VITAMIN SUPPLEMENTS 66
- 7.2.2 PROTEIN SUPPLEMENTS 66
- 7.2.3 FATTY ACID SUPPLEMENTS 66
- 7.2.4 CREATINE 66
- 7.2.5 WHEY PROTEINS 66
- 7.2.6 L-CARNITINE 66
- 7.2.7 SOY 66
- 7.2.8 BETA-ALANINE 66
- 7.2.9 OSTARINE 66
- 7.2.10 COLLAGEN PEPTIDES 66
- 7.2.11 LIGANDROL 67
- 7.2.12 BRANCH-CHAIN AMINO ACIDS 67
- 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 67
- 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 67
- 7.2.15 OTHERS 67
7.3 MEDICATIONS 67
- 7.3.1 OFF LABEL DRUGS 68
- 7.3.2 EMERGING DRUGS 68
  - 7.3.2.1 ACE INHIBITORS 68
  - 7.3.2.2 APPETITE STIMULANTS 68
  - 7.3.2.3 ORAL ANTIDIABETIC DRUGS 68
  - 7.3.2.4 OTHERS 69
7.4 OTHERS 69

8 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE 70

8.1 OVERVIEW 71
8.2 PRIMARY SARCOPENIA 74
- 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 74
- 8.2.2 MEDICATIONS 74
- 8.2.3 OTHERS 74
8.3 SECONDARY SARCOPENIA 75
- 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 75
- 8.3.2 MEDICATIONS 75
- 8.3.3 OTHERS 75

9 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES 76

9.1 OVERVIEW 77
9.2 PRE-SARCOPENIA 80
9.3 SARCOPENIA 80
9.4 SEVERE SARCOPENIA 81

10 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82

10.1 OVERVIEW 83
10.2 ORAL 86
10.3 INJECTABLES 86
10.4 OTHERS 87

11 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER 88

11.1 OVERVIEW 89
11.2 MALE 92
11.3 FEMALE 92

12 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER 93

12.1 OVERVIEW 94
12.2 HOSPITALS 97
- 12.2.1 PUBLIC 97
- 12.2.2 PRIVATE 97
12.3 SPECIALTY CLINICS 98
12.4 HOME HEALTHCARE 98
12.5 OTHERS 99

13 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 100

13.1 OVERVIEW 101
13.2 DIRECT TENDER 104
13.3 RETAIL SALES 104
- 13.3.1 HOSPITAL PHARMACIES 105
- 13.3.2 ONLINE PHARMACIES 105
- 13.3.3 OTHERS 105
13.4 OTHERS 105

14 EUROPE SARCOPENIA TREATMENT MARKET, BY REGION 106

14.1 EUROPE 109
- 14.1.1 GERMANY 116
- 14.1.2 FRANCE 122
- 14.1.3 U.K. 128
- 14.1.4 ITALY 134
- 14.1.5 SPAIN 140
- 14.1.6 RUSSIA 146
- 14.1.7 TURKEY 152
- 14.1.8 BELGIUM 158
- 14.1.9 NETHERLANDS 164
- 14.1.10 SWITZERLAND 170
- 14.1.11 DENMARK 176
- 14.1.12 NORWAY 182
- 14.1.13 SWEDEN 188
- 14.1.14 POLAND 194
- 14.1.15 FINLAND 201
- 14.1.16 REST OF EUROPE 207

15 EUROPE SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 208

15.1 COMPANY SHARE ANALYSIS: EUROPE 208

16 SWOT ANALYSIS 209

17 COMPANY PROFILE 210

17.1 ABBOTT 210
- 17.1.1 COMPANY SNAPSHOT 210
- 17.1.2 REVENUE ANALYSIS 210
- 17.1.3 COMPANY SHARE ANALYSIS 211
- 17.1.4 PRODUCT PORTFOLIO 211
- 17.1.5 RECENT DEVELOPMENT 211
17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 212
- 17.2.1 COMPANY SNAPSHOT 212
- 17.2.2 REVENUE ANALYSIS 212
- 17.2.3 COMPANY SHARE ANALYSIS 213
- 17.2.4 PRODUCT PORTFOLIO 213
- 17.2.5 RECENT DEVELOPMENT 213
17.3 NOVARTIS AG 214
- 17.3.1 COMPANY SNAPSHOT 214
- 17.3.2 REVENUE ANALYSIS 214
- 17.3.3 COMPANY SHARE ANALYSIS 215
- 17.3.4 PRODUCT PORTFOLIO 215
- 17.3.5 PIPELINE PORTFOLIO 215
- 17.3.6 RECENT DEVELOPMENT 215
17.4 SANOFI 216
- 17.4.1 COMPANY SNAPSHOT 216
- 17.4.2 REVENUE ANALYSIS 216
- 17.4.3 COMPANY SHARE ANALYSIS 217
- 17.4.4 PRODUCT PORTFOLIO 217
- 17.4.5 RECENT DEVELOPMENT 217
17.5 HALEON GROUP OF COMPANIES. 218
- 17.5.1 COMPANY SNAPSHOT 218
- 17.5.2 REVENUE ANALYSIS 218
- 17.5.3 COMPANY SHARE ANALYSIS 219
- 17.5.4 PRODUCT PORTFOLIO 219
- 17.5.5 RECENT DEVELOPMENT 219
17.6 ASTAREAL CO., LTD. 220
- 17.6.1 COMPANY SNAPSHOT 220
- 17.6.2 PRODUCT PORTFOLIO 220
- 17.6.3 RECENT DEVELOPMENT 220
17.7 BASF SE 221
- 17.7.1 COMPANY SNAPSHOT 221
- 17.7.2 REVENUE ANALYSIS 221
- 17.7.3 PRODUCT PORTFOLIO 222
- 17.7.4 RECENT DEVELOPMENT 222
17.8 BIOGEN SA 223
- 17.8.1 COMPANY SNAPSHOT 223
- 17.8.2 PRODUCT PORTFOLIO 223
- 17.8.3 RECENT DEVELOPMENT 223
17.9 BIOTHRIVE SCIENCES 224
- 17.9.1 COMPANY SNAPSHOT 224
- 17.9.2 PRODUCT PORTFOLIO 224
- 17.9.3 RECENT DEVELOPMENT 224
17.10 DSM 225
- 17.10.1 COMPANY SNAPSHOT 225
- 17.10.2 REVENUE ANALYSIS 225
- 17.10.3 PRODUCT PORTFOLIO 226
- 17.10.4 RECENT DEVELOPMENT 226
17.11 FERMENTA BIOTECH LIMITED 227
- 17.11.1 COMPANY SNAPSHOT 227
- 17.11.2 REVENUE ANALYSIS 227
- 17.11.3 PRODUCT PORTFOLIO 228
- 17.11.4 RECENT DEVELOPMENT 228
17.12 HEALING PHARMA INDIA PVT. LTD. 229
- 17.12.1 COMPANY SNAPSHOT 229
- 17.12.2 PRODUCT PORTFOLIO 229
- 17.12.3 RECENT DEVELOPMENT 229
17.13 METAGENICS 230
- 17.13.1 COMPANY SNAPSHOT 230
- 17.13.2 PRODUCT PORTFOLIO 230
- 17.13.3 RECENT DEVELOPMENT 230
17.14 THE VITAMIN COMPANY INDIA 231
- 17.14.1 COMPANY SNAPSHOT 231
- 17.14.2 PRODUCT PORTFOLIO 231
- 17.14.3 RECENT DEVELOPMENT 231
17.15 WELLONA PHARMA 232
- 17.15.1 COMPANY SNAPSHOT 232
- 17.15.2 PRODUCT PORTFOLIO 232
- 17.15.3 RECENT DEVELOPMENT 232
17.16 ARMGO PHARMA, INC. 233
- 17.16.1 COMPANY SNAPSHOT 233
- 17.16.2 PIPELINE PORTFOLIO 233
- 17.16.3 RECENT DEVELOPMENT 233
17.17 BIOPHYTIS 234
- 17.17.1 COMPANY SNAPSHOT 234
- 17.17.2 PIPELINE PORTFOLIO 234
- 17.17.3 RECENT DEVELOPMENT 234
17.18 DYSTROGEN THERAPEUTICS CORP 235
- 17.18.1 COMPANY SNAPSHOT 235
- 17.18.2 PIPELINE PORTFOLIO 235
- 17.18.3 RECENT DEVELOPMENT 235
17.19 IMMUNOFORGE INC. 236
- 17.19.1 COMPANY SNAPSHOT 236
- 17.19.2 PIPELINE PORTFOLIO 236
- 17.19.3 RECENT DEVELOPMENT 236
17.20 MYMD PHARMACEUTICALS 237
- 17.20.1 COMPANY SNAPSHOT 237
- 17.20.2 PIPELINE PORTFOLIO 237
- 17.20.3 RECENT DEVELOPMENT 237
17.21 NMD PHARMA A/S 238
- 17.21.1 COMPANY SNAPSHOT 238
- 17.21.2 PIPELINE PORTFOLIO 238
- 17.21.3 RECENT DEVELOPMENT 238
17.22 ONCOCROSS CO., LTD. 239
- 17.22.1 COMPANY SNAPSHOT 239
- 17.22.2 PIPELINE PORTFOLIO 239
- 17.22.3 RECENT DEVELOPMENT 239
17.23 OPKO HEALTH, INC. 240
- 17.23.1 COMPANY SNAPSHOT 240
- 17.23.2 REVENUE ANALYSIS 240
- 17.23.3 PIPELINE PORTFOLIO 241
- 17.23.4 RECENT DEVELOPMENT 241
17.24 REGENERON PHARMACEUTICALS INC. 242
- 17.24.1 COMPANY SNAPSHOT 242
- 17.24.2 REVENUE ANALYSIS 242
- 17.24.3 PIPELINE PORTFOLIO 243
- 17.24.4 RECENT DEVELOPMENT 243
17.25 REJUVENATE BIOMED NV 244
- 17.25.1 COMPANY SNAPSHOT 244
- 17.25.2 PIPELINE PORTFOLIO 244
- 17.25.3 RECENT DEVELOPMENT 244

17.25 REJUVENATE BIOMED NV 244
- 17.25.1 COMPANY SNAPSHOT 244
- 17.25.2 PIPELINE PORTFOLIO 244
- 17.25.3 RECENT DEVELOPMENT 244

18 QUESTIONNAIRE 245

19 RELATED REPORTS 249

LIST OF FIGURES

FIGURE 1 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION 31
FIGURE 2 EUROPE SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 34
FIGURE 3 EUROPE SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 35
FIGURE 4 EUROPE SARCOPENIA TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 EUROPE SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 7 EUROPE SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 39
FIGURE 8 EUROPE SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 40
FIGURE 9 EUROPE SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION 46
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 47
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030 47
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SARCOPENIA TREATMENT MARKET 54
FIGURE 14 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 62
FIGURE 15 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 63
FIGURE 16 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 63
FIGURE 17 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 64
FIGURE 18 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 71
FIGURE 19 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 72
FIGURE 20 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 72
FIGURE 21 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 73
FIGURE 22 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 77
FIGURE 23 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 78
FIGURE 24 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 78
FIGURE 25 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 79
FIGURE 26 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 83
FIGURE 27 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 84
FIGURE 28 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 84
FIGURE 29 EUROPE SARCOPENIA TREATMENT MARKET: LIFELINE CURVE 85
FIGURE 30 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 89
FIGURE 31 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 90
FIGURE 32 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 90
FIGURE 33 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 91
FIGURE 34 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2022 94
FIGURE 35 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 95
FIGURE 36 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 95
FIGURE 37 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 96
FIGURE 38 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 101
FIGURE 39 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 102
FIGURE 40 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 102
FIGURE 41 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 103
FIGURE 42 EUROPE SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 107
FIGURE 43 EUROPE SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%) 208